Clinical Trials in Predementia Stages of Alzheimer Disease

被引:43
|
作者
Pillai, Jagan A. [1 ]
Cummings, Jeffrey L. [2 ]
机构
[1] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44195 USA
[2] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA
关键词
Preclinical Alzheimer's disease; Prodromal Alzheimer's disease; Mild cognitive impairment; At-risk population; Clinical trial designs; Outcome measures; Primary prevention; Secondary prevention; MILD COGNITIVE IMPAIRMENT; PREVENTION INSTRUMENT PROJECT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; CSF BIOMARKERS; AMYLOID-BETA(1-42) BIOMARKER; DISABILITY ASSESSMENT; RESOURCE UTILIZATION; CORTICAL THICKNESS;
D O I
10.1016/j.mcna.2013.01.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effective treatments of Alzheimer disease (AD) dementia are an urgent necessity. There is a growing consensus that effective disease-modifying treatment before the onset of clinical dementia and slowing the progression of mild symptoms are needed after recent setbacks in AD therapeutics. The identification of at-risk and preclinical AD populations is becoming important for targeting primary and secondary prevention clinical trials in AD. This article reviews the strategies and challenges in targeting at-risk and preclinical AD populations for a new generation of AD clinical trials. Design, outcome measures, and complexities in successfully completing a clinical trial targeting this population are reviewed.
引用
收藏
页码:439 / +
页数:20
相关论文
共 50 条
  • [1] Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
    Holland, Dominic
    McEvoy, Linda K.
    Desikan, Rahul S.
    Dale, Anders M.
    [J]. PLOS ONE, 2012, 7 (10):
  • [2] Cerebral perfusion in the predementia stages of Alzheimer's disease
    Binnewijzend, Maja A. A.
    Benedictus, Marije R.
    Kuijer, Joost P. A.
    van der Flier, Wiesje M.
    Teunissen, Charlotte E.
    Prins, Niels D.
    Wattjes, Mike P.
    van Berckel, Bart N. M.
    Scheltens, Philip
    Barkhof, Frederik
    [J]. EUROPEAN RADIOLOGY, 2016, 26 (02) : 506 - 514
  • [3] Cerebral perfusion in the predementia stages of Alzheimer’s disease
    Maja A. A. Binnewijzend
    Marije R. Benedictus
    Joost P. A. Kuijer
    Wiesje M. van der Flier
    Charlotte E. Teunissen
    Niels D. Prins
    Mike P. Wattjes
    Bart N.M. van Berckel
    Philip Scheltens
    Frederik Barkhof
    [J]. European Radiology, 2016, 26 : 506 - 514
  • [4] Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease
    Hill, Derek L. G.
    Schwarz, Adam J.
    Isaac, Maria
    Pani, Luca
    Vamvakas, Spiros
    Hemmings, Robert
    Carrillo, Maria C.
    Yu, Peng
    Sun, Jia
    Beckett, Laurel
    Boccardi, Marina
    Brewer, James
    Brumfield, Martha
    Cantillon, Marc
    Cole, Patricia E.
    Fox, Nick
    Frisoni, Giovanni B.
    Jack, Clifford
    Kelleher, Thomas
    Luo, Feng
    Novak, Gerald
    Maguire, Paul
    Meibach, Richard
    Patterson, Patricia
    Bain, Lisa
    Sampaio, Cristina
    Raunig, David
    Soares, Holly
    Suhy, Joyce
    Wang, Huanli
    Wolz, Robin
    Stephenson, Diane
    [J]. ALZHEIMERS & DEMENTIA, 2014, 10 (04) : 421 - 429
  • [5] The predementia diagnosis of Alzheimer disease
    Frisoni, GB
    Padovani, A
    Wahlund, LO
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2004, 18 (02): : 51 - 53
  • [6] Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages
    Pereira, Joana B.
    Strandberg, Tor Olof
    Palmqvist, Sebastian
    Volpe, Giovanni
    van Westen, Danielle
    Westman, Eric
    Hansson, Oskar
    [J]. CEREBRAL CORTEX, 2018, 28 (01) : 340 - 349
  • [7] Development of screening guidelines and clinical criteria for predementia Alzheimer's disease
    Visser, P. J.
    Verhey, F. R. J.
    Boada, M.
    Bullock, R.
    De Deyn, P. P.
    Frisoni, G. B.
    Froelich, L.
    Hampel, H.
    Jolles, J.
    Jones, R.
    Minthon, L.
    Nobili, F.
    Rikkert, M. Olde
    Ousset, P. -J.
    Rigaud, A. -S.
    Scheltens, P.
    Soininen, H.
    Spiru, L.
    Touchon, J.
    Tsolaki, M.
    Vellas, B.
    Wahlund, L. -O.
    Wilcock, G.
    Winblad, B.
    [J]. NEUROEPIDEMIOLOGY, 2008, 30 (04) : 254 - 265
  • [8] Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
    Grill, Joshua D.
    Di, Lijie
    Lu, Po H.
    Lee, Cathy
    Ringman, John
    Apostolova, Liana G.
    Chow, Nicole
    Kohannim, Omid
    Cummings, Jeffrey L.
    Thompson, Paul M.
    Elashoff, David
    [J]. NEUROBIOLOGY OF AGING, 2013, 34 (01) : 62 - 72
  • [9] Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
    Visser, PJ
    Scheltens, P
    Verhey, FRJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (10): : 1348 - 1354
  • [10] PET tau and amyloid levels in default mode network synergistically determine clinical status in predementia stages of Alzheimer's disease
    Pascoal, T. A.
    Mathotaarachchi, S.
    Shin, M.
    Kang, M. S.
    Ng, K. P.
    Soucy, J. -P.
    Gauthier, S.
    Rosa-Neto, P.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 87 - 87